Leede Financial Issues Negative Estimate for TSE:TH Earnings

Theratechnologies Inc. (TSE:TH) – Research analysts at Leede Financial dropped their FY2026 EPS estimates for Theratechnologies in a research report issued on Monday, April 14th. Leede Financial analyst D. Loe now forecasts that the company will post earnings per share of $0.20 for the year, down from their prior forecast of $0.21. The consensus estimate for Theratechnologies’ current full-year earnings is $0.03 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.28 EPS.

Other analysts have also issued research reports about the company. Research Capitl upgraded Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th. Jones Trading upgraded Theratechnologies from a “hold” rating to a “strong-buy” rating in a research note on Friday, April 11th.

Theratechnologies Trading Down 3.5 %

Shares of TSE:TH opened at C$3.58 on Tuesday. The company’s 50-day moving average price is C$2.39 and its two-hundred day moving average price is C$2.18. Theratechnologies has a one year low of C$1.59 and a one year high of C$4.33. The company has a debt-to-equity ratio of -293.92, a current ratio of 1.08 and a quick ratio of 0.64. The stock has a market capitalization of C$114.22 million, a PE ratio of -40.52, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.